| Literature DB >> 25856668 |
McKinsey L Goodenberger1, Brittany C Thomas1, Douglas Riegert-Johnson2, C Richard Boland3, Sharon E Plon4, Mark Clendenning5, Aung Ko Win6, Leigha Senter7, Steven M Lipkin8, Zsofia K Stadler9, Finlay A Macrae10, Henry T Lynch11, Jeffrey N Weitzel12, Albert de la Chapelle7, Sapna Syngal13, Patrick Lynch14, Susan Parry15, Mark A Jenkins6, Steven Gallinger16, Spring Holter16, Melyssa Aronson16, Polly A Newcomb17, Terrilea Burnett18, Loïc Le Marchand18, Pavel Pichurin19, Heather Hampel7, Jonathan P Terdiman20, Karen H Lu21, Stephen Thibodeau1, Noralane M Lindor22.
Abstract
Germ-line mutations in MLH1, MSH2, MSH6, and PMS2 have been shown to cause Lynch syndrome. The penetrance of the cancer and tumor spectrum has been repeatedly studied, and multiple professional societies have proposed clinical management guidelines for affected individuals. Several studies have demonstrated a reduced penetrance for monoallelic carriers of PMS2 mutations compared with the other mismatch repair (MMR) genes, but clinical management guidelines have largely proposed the same screening recommendations for all MMR gene carriers. The authors considered whether enough evidence existed to propose new screening guidelines specific to PMS2 mutation carriers with regard to age at onset and frequency of colonic screening. Published reports of PMS2 germ-line mutations were combined with unpublished cases from the authors' research registries and clinical practices, and a discussion of potential modification of cancer screening guidelines was pursued. A total of 234 monoallelic PMS2 mutation carriers from 170 families were included. Approximately 8% of those with colorectal cancer (CRC) were diagnosed before age 30, and each of these tumors presented on the left side of the colon. As it is currently unknown what causes the early onset of CRC in some families with monoallelic PMS2 germline mutations, the authors recommend against reducing cancer surveillance guidelines in families found having monoallelic PMS2 mutations in spite of the reduced penetrance.Genet Med 18 1, 13-19.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25856668 PMCID: PMC4834863 DOI: 10.1038/gim.2015.27
Source DB: PubMed Journal: Genet Med ISSN: 1098-3600 Impact factor: 8.822